Another checkpoint inhibitor study, KEYNOTE-355 [141], compared pembrolizumab (anti-PD1) with nab-paclitaxel, paclitaxel or carboplatin and gemcitabine in first-line therapy for metastatic TNBC patients and reported improved progression-free survival and OS in PD-L1-positive tumours (combined positive score (CPS) of >10) and led to the approval of pembrolizumab. The gene discussed is CD274; the disease is neoplasm.